Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 12/20 | 0.36 |
| ▸ | MC4R | P32245 | 4/20 | 0.36 |
| ▸ | MC5R | P33032 | 1/20 | 0.36 |
| ▸ | MC3R | P41968 | 1/20 | 0.36 |
| ▸ | MC1R | Q01726 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6047771 | 0.89 | PDE10A (0.37) | PDE10A | |
| SCHEMBL6047779 | 0.88 | PDE10A (0.35) | PDE10AMC4RMC5RMC3RMC1R | |
| SCHEMBL6047811 | 0.82 | — | — | |
| SCHEMBL6047760 | 0.82 | CYP1A2 (0.38) | — | |
| SCHEMBL4311738 | 0.81 | PDE10A (0.35) | PDE10AMC4RMC5RMC3RMC1R | |
| SCHEMBL6047818 | 0.80 | MC4R (0.48) | MC4RMC5RMC3RMC1R | |
| SCHEMBL6047790 | 0.80 | ROCK1 (0.37) | MC4RMC5RMC3RMC1R | |
| SCHEMBL4310149 | 0.77 | PDE10A (0.34) | PDE10AMC4R | |
| SCHEMBL6047785 | 0.76 | MC4R (0.32) | MC4RMC5RMC3RMC1R | |
| SCHEMBL4697988 | 0.76 | MC4R (0.46) | MC4RMC5RMC3RMC1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148805-A1 | Opthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME CORP. | 2006-07-06 | — | — | US | claimed |
| US-20060148805-A1 | Opthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME CORP. | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148805-A1 | Opthalmic compositions for treating ocular hypertension | KCNH2, KCNH3, KCNN1 | PDE10A 464/4885MC4R 1970/4885MC5R 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.